文献速递外周动脉疾病

BASIL-2在CLTI患者中的外部验证:旁路手术与血管成形术±支架对比

Validation of BASIL-2 among patients undergoing primary bypass or angioplasty with or without stenting for chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2025-06-04

本研究回顾性纳入2005-2022年1184条因慢性肢体威胁性缺血(CLTI)行首次膝下血运重建的肢体,经倾向匹配后比较开放旁路(BPG)与血管成形术±支架(PTA/S)。匹配后两组无基线差异,围术期并发症及5年无截肢生存(AFS)、再干预、大截肢、MALE均无显著差异。限制BPG为单段大隐静脉(ssGSV)时,再干预和MALE显著低于PTA/S(HR 0.52和0.69),提示该 conduit 的获益。

要点

  • ssGSV旁路较PTA/S显著降低再干预(HR 0.52)和MALE(HR 0.69)。

核心结论

  • 在膝下动脉血运重建的CLTI患者中,BPG与PTA/S在AFS上无差异,提示BASIL-2结果的可推广性存疑。
  • 采用ssGSV的BPG较PTA/S显著降低再次干预和MALE发生率。

研究设计与样本

  • 回顾性队列研究,纳入2005-2022年单中心1184条因CLTI行首次膝下血运重建的肢体,其中BPG 490条、PTA/S 694条。
  • 采用一对一倾向性匹配模拟BASIL-2标准,匹配后纳入620例(BPG 310例,PTA/S 310例)。
  • 主要结局为无截肢生存(AFS);次要结局包括围术期并发症、再次干预、大截肢和MALE。

主要发现

  • 匹配后两组基线无差异:平均年龄均为71.0岁;男性64% vs 66%;白人74% vs 75%;冠心病49% vs 52%;糖尿病75% vs 77%;慢性肾病27% vs 34%;透析依赖17% vs 19%;吸烟史65% vs 66%。
  • 限制BPG为ssGSV(n=267)时,AFS BPG 32% vs PTA/S 36%(无显著差异),再次干预12% vs 19%(HR 0.52,95%CI 0.30-0.89),MALE 29% vs 36%(HR 0.69,95%CI 0.49-0.98)。

关键数值与推荐

  • ssGSV旁路与PTA/S相比:再次干预风险降低48%(HR 0.52,95%CI 0.30-0.89);MALE风险降低30%(HR 0.69,95%CI 0.49-0.98)。

临床怎么用

  • 对于适合ssGSV旁路的CLTI患者,ssGSV旁路较PTA/S可降低再次干预和MALE风险。
  • 在膝下动脉血运重建中,BPG与PTA/S在无截肢生存上无差异,选择术式需综合评估。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: BASIL-2 demonstrated the superiority of an endovascular-first approach in patients with chronic limb-threatening ischemia (CLTI) for the primary endpoint of amputation-free survival (AFS); however, the generalizability of these data are unknown. Thus, we aimed to externally validate these findings by comparing open surgical bypass (BPG) to angioplasty ± stenting (PTA/S), using the BASIL-2 inclusion and randomization criteria. METHODS: All patients undergoing a first-time lower extremity infrapopliteal revascularization for CLTI at our institution from 2005 to 2022 were retrospectively reviewed. To approximate BASIL-2, one-to-one propensity matching was performed. The primary outcome was AFS; secondary outcomes included perioperative complications, major reintervention, major amputation, and major adverse limb events (MALE). A sensitivity analysis was performed assessing the same PTA/S cohort vs BPG with only single-segment great saphenous vein (ssGSV) conduits. Outcomes in the matched cohorts were evaluated using χ2, Kaplan-Meier, and Cox regression analyses. RESULTS: Of 1184 limbs undergoing a first-time infrapopliteal intervention for CLTI between 2005 and 2022, 490 underwent BPG, and 694 underwent PTA/S. After matching, 620 patients (310 BPG and 310 PTA/S) fit our criteria, with no baseline differences noted between groups. Between BPG and PTA/S, the mean age was 71.0 years in both groups, with similar rates of male sex (64% vs 66%), White race (74% vs 75%), coronary artery disease (49% vs 52%), diabetes (75% vs 77%), chronic kidney disease (27% vs 34%), dialysis dependence (17% vs 19%), and smoking history (65% vs 66%). There were no differences in perioperative mortality (4.5% vs 3.9%), stroke (1.0% vs 0.0%), myocardial infarction (2.9% vs 1.3%), or acute kidney injury (12% vs 16%) (all P > .05). BPG, as compared with PTA/S, did not demonstrate any difference in AFS (at 5 years, 36% vs 39%), major reintervention (15% vs 19%), major amputation (24% vs 22%), or MALE (32% vs 36%) (all P > .05). When limiting the BPG group to only ssGSV conduits (n = 267), despite no difference seen in AFS (32% vs 36%), we noted significantly lower rates of major reintervention (12% vs 19%) and MALE (29% vs 36%), demonstrating a 48% and 30% risk reduction, respectively (hazard ratio, 0.52; 95% confidence interval, 0.30-0.89 and 0.69; 95% confidence interval, 0.49-0.98). CONCLUSIONS: Among patients undergoing infrapopliteal revascularization for CLTI, BPG and PTA/S do not differ in regard to AFS, raising concerns regarding the generalizability of BASIL-2. Importantly, infrapopliteal interventions following ssGSV BPG, as compared with PTA/S, do demonstrate significantly lower rates of major reintervention and MALE, reinforcing the benefits of this conduit in patients with CLTI.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Darling JD, Guetter CR, Caron E, et al. Validation of BASIL-2 among patients undergoing primary bypass or angioplasty with or without stenting for chronic limb-threatening ischemia. J Vasc Surg. 2025. PMID: 40480618. doi:10.1016/j.jvs.2025.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。